Mesoridazine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Mesoridazine
Mesoridazine.png
Mesoridazine3Dan2.gif
Systematic (IUPAC) name
10-{2-[(RS)1-Methylpiperidin-2-yl]ethyl}- 2-methylsulfinyl- 10H-phenothiazine
Clinical data
Trade names Serentil
AHFS/Drugs.com Micromedex Detailed Consumer Information
MedlinePlus a682306
  • US: C (Risk not ruled out)
  • (Prescription only)
oral, intravenous
Pharmacokinetic data
Protein binding 4%
Metabolism Hepatic/Renal
Half-life 24 to 48 hours
Excretion Biliary and renal
Identifiers
5588-33-0 YesY
N05AC03
PubChem CID 4078
DrugBank DB00933 YesY
ChemSpider 3936 YesY
UNII 5XE4NWM740 YesY
KEGG D02671 YesY
ChEBI CHEBI:6780 YesY
ChEMBL CHEMBL1088 YesY
Chemical data
Formula C21H26N2OS2
386.576 g/mol
Physical data
Melting point 130 °C (266 °F)
insoluble mg/mL (20 °C)
 YesY (what is this?)  (verify)

Mesoridazine (Serentil) is a piperidine neuroleptic drug belonging to the class of drugs called phenothiazines, used in the treatment of schizophrenia. It is a metabolite of thioridazine. The drug's name is derived from the methylsulfoxy and piperidine functional groups in its chemical structure.

It has central antiadrenergic, antidopaminergic, antiserotonergic and weak muscarinic anticholinergic effects.

Serious side effects include akathisia, tardive dyskinesia and the potentially fatal neuroleptic malignant syndrome.

Mesoridazine was withdrawn from the United States market in 2004 due to dangerous side effects, namely irregular heart beat and QT-prolongation of the electrocardiogram.[1]

It currently appears to be unavailable worldwide.

References[edit]

  1. ^ [1]